EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

From T cell engagers to next-generation immune cell engagers for cancer immunotherapy

Zaopeng Yang iD, Yang-Xin Fu

Antibody Therapeutics · 29.06.2026 · 9 (3) · 381-394

DOI: 10.1093/abt/tbag030 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Antibody Therapeutics, online erschienen am 01.06.2026. Verfasst von Zaopeng Yang und 1 weiteren Autor:innen. Beteiligte Einrichtung: Changping Laboratory, Beijing 102206, China. Die Arbeit nennt 131 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Noncommunicable Chronic Diseases-National Science and Technology Major Project.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immune cell engagers have emerged as a powerful class of multi-specific therapeutics that redirect immune effector cells toward tumor cells to induce targeted cytotoxicity. Among these, T cell engagers (TCEs) represent the most clinically advanced platform, with multiple approved agents demonstrating substantial efficacy in hematologic malignancies. However, their broader application remains limited by systemic toxicities, antigen heterogeneity, and reduced efficacy in solid tumors. To address these challenges, next-generation TCEs are being engineered with improved selectivity, and optimized signaling properties. In parallel, increasing attention has shifted toward engaging alternative immune effectors, including γδ T cells, natural killer cells, and myeloid populations, which provide complementary mechanisms of tumor recognition and immune modulation. In this Review, we summarize the biological principles underlying T or other immune cell engagers, highlight emerging alternative platforms, and discuss evolving engineering strategies that are shaping the future of programmable cancer immunotherapy.

Schlagwörter

Stichwörter der Autor:innen

NK cell engagersT cell engagerscancer immunotherapyimmune cell engagersmyeloid cell engagersγδ T cells

Autor:innen und Institutionen

  • Changping Laboratory, Beijing 102206, China.
  • Center for Cancer Biology, School of Basic Medical Sciences, Tsinghua University, Beijing 100084, China.
  • State Key Laboratory of Molecular Oncology, Tsinghua University, Beijing 100084, China.

ORCID-Profile: Zaopeng Yang

Förderung

  • Noncommunicable Chronic Diseases-National Science and Technology Major Project

Zitieren

APA

Yang, Z., & Fu, Y. X. (2026). From T cell engagers to next-generation immune cell engagers for cancer immunotherapy. Antibody Therapeutics, 9(3), 381-394. https://doi.org/10.1093/abt/tbag030

Vancouver

Yang Z, Fu YX. From T cell engagers to next-generation immune cell engagers for cancer immunotherapy. Antibody Therapeutics. 2026;9(3):381-394. doi:10.1093/abt/tbag030

BibTeX
@article{Yang2026,
  author = {Yang, Zaopeng and Fu, Yang-Xin},
  title = {From T cell engagers to next-generation immune cell engagers for cancer immunotherapy},
  journal = {Antibody Therapeutics},
  year = {2026},
  volume = {9},
  number = {3},
  pages = {381--394},
  doi = {10.1093/abt/tbag030}
}
Kostenlos starten →